Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Colon Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 35 active trials
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 9 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Camrelizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2024 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| CTLA-4 Inhibitor | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 14, 2026 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Mitomycin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 12, 2023 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 21, 2026 |
| Raltitrexed | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2024-11 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Selpercatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 2, 2017 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tislelizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 1, 2022 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Regorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2015-02 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2001-12 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-10 |
| Gemcitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Feb 11, 2005 |
| Metformin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-08 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-06 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-08 |
| Conatumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-10 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 21, 2018 |
| FOLFOX-6 Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-05 |
| Linifanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-10 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-08 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-07 |
| Azacitidine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-04 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 15, 2019 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-05 |
| Denosumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 16, 2009 |
| Ganetespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-04 |
| Ganitumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 27, 2008 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-10 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-09 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 24, 2018 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-05 |
| Melphalan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1999-04 |
| MVT Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 13, 2019 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 8, 2015 |
| Niraparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 15, 2022 |
| Peginterferon Alfa-2a | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 14, 2023 |
| Ramucirumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-08 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.